echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Simcere Pharmaceutical's "Idoxaban Toluenesulfonate Tablets" Declared for Listing

    Simcere Pharmaceutical's "Idoxaban Toluenesulfonate Tablets" Declared for Listing

    • Last Update: 2021-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 2, the Insight database showed that Hainan Simcere Pharmaceutical’s application for the listing of 4 types of generic drug idoxaban tosylate tablets was accepted (acceptance number: CYHS2101233/4/5) for the treatment of stroke and atrial fibrillation To prevent systemic embolism, it is the first domestic producer of this species.


    Idoxaban tosylate was developed by Daiichi Sankyo, and was first marketed in Japan in April 2011 for venous thromboembolism (VTE).


    Officially entered China in December 2018 for patients with one or more risk factors (such as congestive heart failure, hypertension, age ≥75 years, diabetes, history of previous stroke or transient ischemic attack (TIA)) Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF).


    Public data shows that the global sales of Edoxaban in 2020 will be 16.


    On December 28, 2020, the new version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" was officially announced.


    According to the Insight database, as of now, many companies’ generic drug products have been approved for clinical trials.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.